132 related articles for article (PubMed ID: 8597087)
1. Antisense phosphorothioate oligodeoxynucleotides: introductory concepts and possible molecular mechanisms of toxicity.
Zon G
Toxicol Lett; 1995 Dec; 82-83():419-24. PubMed ID: 8597087
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides.
Henry SP; Monteith D; Levin AA
Anticancer Drug Des; 1997 Jul; 12(5):395-408. PubMed ID: 9236855
[No Abstract] [Full Text] [Related]
3. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides.
Agrawal S
Biochim Biophys Acta; 1999 Dec; 1489(1):53-68. PubMed ID: 10806997
[TBL] [Abstract][Full Text] [Related]
4. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents.
Brysch W; Schlingensiepen KH
Cell Mol Neurobiol; 1994 Oct; 14(5):557-68. PubMed ID: 7621513
[TBL] [Abstract][Full Text] [Related]
5. Antisense therapeutics.
Agrawal S; Zhao Q
Curr Opin Chem Biol; 1998 Aug; 2(4):519-28. PubMed ID: 9736926
[TBL] [Abstract][Full Text] [Related]
6. Toxicological properties of several novel oligonucleotide analogs in mice.
Henry SP; Zuckerman JE; Rojko J; Hall WC; Harman RJ; Kitchen D; Crooke ST
Anticancer Drug Des; 1997 Jan; 12(1):1-14. PubMed ID: 9051110
[TBL] [Abstract][Full Text] [Related]
7. [The toxic effects of high-dose Bcl-2 antisense phosphorothioate oligodeoxynucleotides incubation on cell line].
Lin Y; Lü L; Chen Z
Zhonghua Yi Xue Za Zhi; 2000 Sep; 80(9):694-7. PubMed ID: 11798838
[TBL] [Abstract][Full Text] [Related]
8. Synthetic oligonucleotides: the development of antisense therapeutics.
Monteith DK; Levin AA
Toxicol Pathol; 1999; 27(1):8-13. PubMed ID: 10367666
[TBL] [Abstract][Full Text] [Related]
9. The stability, toxicity and effectiveness of unmodified and phosphorothioate antisense oligodeoxynucleotides in Xenopus oocytes and embryos.
Woolf TM; Jennings CG; Rebagliati M; Melton DA
Nucleic Acids Res; 1990 Apr; 18(7):1763-9. PubMed ID: 1692405
[TBL] [Abstract][Full Text] [Related]
10. Progress in antisense oligonucleotide therapeutics.
Crooke ST; Bennett CF
Annu Rev Pharmacol Toxicol; 1996; 36():107-29. PubMed ID: 8725384
[TBL] [Abstract][Full Text] [Related]
11. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides.
Srinivasan SK; Iversen P
J Clin Lab Anal; 1995; 9(2):129-37. PubMed ID: 7714665
[No Abstract] [Full Text] [Related]
12. Antisense phosphorothioate oligonucleotides: selective killing of the intracellular parasite Leishmania amazonensis.
Ramazeilles C; Mishra RK; Moreau S; Pascolo E; Toulmé JJ
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7859-63. PubMed ID: 8058724
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys.
Monteith DK; Horner MJ; Gillett NA; Butler M; Geary R; Burckin T; Ushiro-Watanabe T; Levin AA
Toxicol Pathol; 1999; 27(3):307-17. PubMed ID: 10356707
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
Dean N; McKay R; Miraglia L; Howard R; Cooper S; Giddings J; Nicklin P; Meister L; Ziel R; Geiger T; Muller M; Fabbro D
Cancer Res; 1996 Aug; 56(15):3499-507. PubMed ID: 8758918
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice.
Henry SP; Taylor J; Midgley L; Levin AA; Kornbrust DJ
Antisense Nucleic Acid Drug Dev; 1997 Oct; 7(5):473-81. PubMed ID: 9361906
[TBL] [Abstract][Full Text] [Related]
16. In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides.
Moriya K; Matsukura M; Kurokawa K; Koike K
Biochem Biophys Res Commun; 1996 Jan; 218(1):217-23. PubMed ID: 8573134
[TBL] [Abstract][Full Text] [Related]
17. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1.
Henry SP; Templin MV; Gillett N; Rojko J; Levin AA
Toxicol Pathol; 1999; 27(1):95-100. PubMed ID: 10367680
[TBL] [Abstract][Full Text] [Related]
18. Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety.
Schlingensiepen R; Goldbrunner M; Szyrach MN; Stauder G; Jachimczak P; Bogdahn U; Schulmeyer F; Hau P; Schlingensiepen KH
Oligonucleotides; 2005; 15(2):94-104. PubMed ID: 15989424
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.
Henry SP; Bolte H; Auletta C; Kornbrust DJ
Toxicology; 1997 Jun; 120(2):145-55. PubMed ID: 9184201
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man.
Iversen PL; Copple BL; Tewary HK
Toxicol Lett; 1995 Dec; 82-83():425-30. PubMed ID: 8597088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
